Loading patent…
AssigneeG.L. Pharma GmbH
InventorsGeorg Guebitz, Katrin Greimel, Martin Brandauer, Daniela Huber, Klaus Bleymaier, Wolfgang Kroutil, Doris Lechner, Christof Wachter, Harald Wagner, Heimo Winkler
Estimating the term…
Disclosed is an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group (a drug-processing enzyme), wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug.
An abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group, wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug, wherein the enzyme catalyses O-dealkylation, N-dealkylation, keto-reduction, N-oxidation, epoxy-hydroxylation, esterification, de-amidation, or dehalogenation of the drug or addition of molecules to the drug, wherein the composition comprises a drug/enzyme combination selected from the group consisting morphine/laccase, tapentadol/laccase, oxymorphone/laccase, hydromorphone/laccase, pentazocine/laccase, buprenorphine/laccase, diacetylmorphine/hydrolase/laccase, levorphanol/laccase, and oxycodone/laccase/oxycodone-processing enzyme.
Dependencies are inferred from the claim text.